NCT06778330Completed
The Effect of Combination of Dapagliflozin and Sildenafil in Treatment of Heart Failure Patients With Secondary Pulmonary Hypertension
Source: ClinicalTrials.gov · Last updated 3 Sept 2025
Brief summary (registry, in English)
This study aims to determine the efficacy of sildenafil (improve PAH) as an add-on therapy to dapagliflozin in the treatment of heart failure patients with secondary pulmonary arterial hypertension and compare the result with monotherapy dapagliflozin
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 100 (actual)
- First submitted
- 9 Jan 2025
- Start date
- 20 Jan 2025
- Primary completion date
- 1 Aug 2025
- Lead sponsor
- Fayoum University
- NCT number
- NCT06778330
What you commit to
- Study type: Interventional
- Participants enrolled: 100
- From 20 Jan 2025 to the primary completion date, 1 Aug 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with a history of severe allergic reactions or hypersensitivity to sildenafil, dapagliflozin, or related medications.
- Patients with pulmonary arterial hypertension (PAH) due to conditions other than heart failure (e.g., idiopathic PAH).
- severe hepatic impairment
- valvular heart disease .
- Patients with a known or suspected history of non-compliance with medical treatment or inability to adhere to study procedures.
Age
- aged less than 18 years.
Other
- Individuals with contraindications to the use of sildenafil or dapagliflozin.
- life expectancy of less than 6 months .
- Pregnant or breastfeeding women
Who the study is looking for
- patients with established heart failure with secondary pulmonary hypertension seen by a primary care provider to diagnose a heart disease, the patient's symptoms which may experience:
- Dizziness or fainting
- Heart palpitations, which may feel like your heart fluttering or skipping beats
- Shortness of breath
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fayoum University Coordinator of this site? Confirm its status | Al Fayyum | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.